TY -的T1 -一个血嗜酸性粒细胞计数意味着surement is as good as two for prediction of ICS treatment response in the IMPACT trial JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.04522-2020 VL - 58 IS - 3 SP - 2004522 AU - Bafadhel, Mona AU - Barnes, Neil AU - Bourke, Stephen C. AU - Compton, Chris AU - Criner, Gerard J. AU - Dransfield, Mark T. AU - Halpin, David M.G. AU - Han, MeiLan K. AU - Hartley, Benjamin AU - Jones, C. Elaine AU - Lange, Peter AU - Lettis, Sally AU - Lipson, David A. AU - Lomas, David A. AU - Martin, Neil AU - Martinez, Fernando J. AU - Wise, Robert AU - Singh, Dave Y1 - 2021/09/01 UR - //www.qdcxjkg.com/content/58/3/2004522.abstract N2 - Blood eosinophil count is a readily available biomarker in COPD that can assist identification of patients most likely to benefit from inhaled corticosteroids (ICS) [1]. Recent evidence has demonstrated a link between blood eosinophil count as a continuous variable and magnitude of response to ICS in terms of exacerbation rate reduction [2, 3]. The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends that blood eosinophil count can be used to predict the likelihood of beneficial response to ICS, in combination with clinical assessment of exacerbation risk [1]. However, as blood eosinophil counts can show variability, particularly at higher levels [4–6], it is of clinical interest to determine how many measurements are sufficient to predict an ICS response in patients with COPD. Data from the InforMing the PAthway of COPD Treatment (IMPACT) trial showed an association between blood eosinophil count and ICS response on reduction of moderate/severe COPD exacerbations [3]. This post hoc analysis of IMPACT compared whether one or two measurements of blood eosinophil count can better predict ICS responses in patients with COPD.This post hoc analysis of the IMPACT trial demonstrated that a single blood eosinophil count measurement is sufficient to predict a beneficial response to inhaled corticosteroids in patients with symptomatic COPD and a history of exacerbations https://bit.ly/3wgeDCUEditorial support (in the form of writing assistance, assembling figures, collating author comments, grammatical editing and referencing) was provided by Eloise Morecroft and Katie Baker, at Fishawack Indicia Ltd, UK, and was funded by GSK. D. Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). D.A. Lomas is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC) and is an NIHR Senior Investigator. ER -